Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy.

TitleBortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy.
Publication TypeJournal Article
Year of Publication2014
AuthorsHartono C, Chung M, Kuo SF, Seshan SV, Muthukumar T
JournalJ Nephrol
Volume27
Issue1
Pagination103-6
Date Published2014 Feb
ISSN1724-6059
KeywordsBoronic Acids, Bortezomib, Female, Glomerulonephritis, Membranous, Humans, Middle Aged, Nephrotic Syndrome, Proteasome Inhibitors, Pyrazines
Abstract

Idiopathic membranous nephropathy is a common cause of nephrotic syndrome in adults. The nephrotic syndrome due to idiopathic membranous nephropathy is often resistant to glucocorticosteroids and requires an alkylating agent such as chlorambucil or cyclophosphamide to induce remission. Recent studies illustrate that antibodies against the autoantigen M-type phospholipase A2 receptor contribute to a vast majority but not all cases of idiopathic membranous nephropathy. Herein, we report a patient with nephrotic syndrome due to membranous nephropathy that was resistant to 6 months of therapy with ramipril and high-dose glucocorticosteroids but responded to a single cycle of bortezomib infusion.

DOI10.1007/s40620-013-0028-x
Alternate JournalJ Nephrol
PubMed ID24430762
Grant ListUL1TR000457 / TR / NCATS NIH HHS / United States
Related Faculty: 
Surya V. Seshan, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700